Earlier medical reports of CagriSema located that it helped patients accomplish substantially greater weight loss than semaglutide (Wegovy) did. Even if Lilly's Zepbound/Mounjaro topples Wegovy, It is possible that CagriSema could enter the industry at the appropriate time for Novo Nordisk to keep its In general Management inside the weight problem